Studies indicate that isoprolactone reduces glucose uptake and lactate production in cisplatin-resistant ovarian cancer cells by targeting LDHA inhibition, increasing the susceptibility of cisplatin, suppressing tumor growth and overcoming resistance (60). The gene discussed is LDHA; the disease is ovarian carcinoma.